TY - JOUR
T1 - Alginate-based microparticles coated with HPMCP/AS cellulose-derivatives enable the Ctx(Ile21)-Ha antimicrobial peptide application as a feed additive
AU - Roque-Borda, Cesar Augusto
AU - Silva, Hanyeny Raiely Leite
AU - Crusca Junior, Edson
AU - Serafim, Jéssica Aparecida
AU - Meneguin, Andréia Bagliotti
AU - Chorilli, Marlus
AU - Macedo, Wagner Costa
AU - Teixeira, Silvio Rainho
AU - Guastalli, Elisabete Aparecida Lopes
AU - Soares, Nilce Maria
AU - Blair, Jessica M A
AU - Pikramenou, Zoe
AU - Vicente, Eduardo Festozo
PY - 2021/7/31
Y1 - 2021/7/31
N2 - Microencapsulation is a potential biotechnological tool, which can overcome antimicrobial peptides (AMP) instabilities and reduce toxic side effects. Thus, this study evaluates the antibacterial activities of the Ctx(Ile21)-Ha AMP against multidrug-resistant (MDR) and non-resistant bacteria and develop and characterize peptide-loaded microparticles coated with the enteric polymers hydroxypropylmethylcellulose acetate succinate (HPMCAS) and hydroxypropylmethylcellulose phthalate (HPMCP). Ctx(Ile21)-Ha was obtained by solid phase peptide synthesis (SPPS) method, purified and characterized by HPLC and Mass Spectrometry. The peptide exhibited potent antibiotic activities against Salmonella enteritidis, Salmonella typhimurium, Pseudomonas aeruginosa (MDR), Acinetobacter baumannii (MDR), and Staphylococcus aureus (MDR). Ctx(Ile21)-Ha microencapsulation was performed by ionic gelation with high efficiency, maintaining the physical-chemical stability. Ctx(Ile21)-Ha coated-microparticles were characterized by DSC, TGA, FTIR-Raman, XRD and SEM. Hemolytic activity assay demonstrated that hemolysis was decreased up to 95% compared to single molecule. In addition, in vitro release control profile simulating different portions of gastrointestinal tract was performed and showed the microcapsules' ability to protect the peptide and release it in the intestine, aiming pathogen's location, mainly by Salmonella sp. Therefore, use of microencapsulated Ctx(Ile21)-Ha can be allowed as an antimicrobial controller in monogastric animal production as an oral feed additive (antimicrobial controller), being a valuable option for molecules with low therapeutic indexes or high hemolytic rates.
AB - Microencapsulation is a potential biotechnological tool, which can overcome antimicrobial peptides (AMP) instabilities and reduce toxic side effects. Thus, this study evaluates the antibacterial activities of the Ctx(Ile21)-Ha AMP against multidrug-resistant (MDR) and non-resistant bacteria and develop and characterize peptide-loaded microparticles coated with the enteric polymers hydroxypropylmethylcellulose acetate succinate (HPMCAS) and hydroxypropylmethylcellulose phthalate (HPMCP). Ctx(Ile21)-Ha was obtained by solid phase peptide synthesis (SPPS) method, purified and characterized by HPLC and Mass Spectrometry. The peptide exhibited potent antibiotic activities against Salmonella enteritidis, Salmonella typhimurium, Pseudomonas aeruginosa (MDR), Acinetobacter baumannii (MDR), and Staphylococcus aureus (MDR). Ctx(Ile21)-Ha microencapsulation was performed by ionic gelation with high efficiency, maintaining the physical-chemical stability. Ctx(Ile21)-Ha coated-microparticles were characterized by DSC, TGA, FTIR-Raman, XRD and SEM. Hemolytic activity assay demonstrated that hemolysis was decreased up to 95% compared to single molecule. In addition, in vitro release control profile simulating different portions of gastrointestinal tract was performed and showed the microcapsules' ability to protect the peptide and release it in the intestine, aiming pathogen's location, mainly by Salmonella sp. Therefore, use of microencapsulated Ctx(Ile21)-Ha can be allowed as an antimicrobial controller in monogastric animal production as an oral feed additive (antimicrobial controller), being a valuable option for molecules with low therapeutic indexes or high hemolytic rates.
KW - Acinetobacter baumannii/drug effects
KW - Alginates/chemistry
KW - Drug Compounding
KW - Food Additives/chemistry
KW - Hemolysis
KW - Methylcellulose/analogs & derivatives
KW - Microbial Sensitivity Tests
KW - Particle Size
KW - Pore Forming Cytotoxic Proteins/chemistry
KW - Pseudomonas aeruginosa/drug effects
KW - Salmonella/drug effects
KW - Staphylococcus aureus/drug effects
U2 - 10.1016/j.ijbiomac.2021.05.011
DO - 10.1016/j.ijbiomac.2021.05.011
M3 - Article
C2 - 33965488
SN - 0141-8130
VL - 183
SP - 1236
EP - 1247
JO - International Journal of Biological Macromolecules
JF - International Journal of Biological Macromolecules
ER -